PeptideNerds
· /bpc-157 · 20 min read

BPC-157 Dosage Guide: How Much to Take, How Often, and For How Long (2026)

Alejandro Reyes

Written by Alejandro Reyes

Founder & Lead Researcher

PN

Reviewed by Peptide Nerds Editorial · Updated March 2026

Important: We are not doctors. Everything in this article is based on published research and publicly available clinical data. It is not medical advice. Talk to your physician before changing any medication or health protocol. BPC-157 is not FDA-approved for any human indication. The FDA has advised compounding pharmacies against producing it.

BPC-157 Dosage: How Much to Take, How Often, and For How Long

In animal studies, researchers most commonly administered BPC-157 at doses of 10 mcg/kg or 10 ng/kg body weight, given once daily via intraperitoneal injection (Staresinic et al., 2003). Translated to a 80 kg human using commonly reported research protocols, that puts the range at roughly 200-800 mcg per day. The dose most frequently reported in the research community is 250-500 mcg daily, often split into two administrations of 250 mcg each.

But those numbers need context. Nearly all BPC-157 dosing data comes from animal studies. There are no large-scale human clinical trials establishing a verified dose for any condition. What follows is a breakdown of what the published literature reports, how researchers have used this compound, and what the data actually supports.

Key Takeaways

  • Animal studies typically used 10 mcg/kg body weight once daily via injection (Staresinic et al., 2003)
  • The most commonly reported research dose in humans is 250-500 mcg per day, often split into two doses
  • Study durations in animal models ranged from 14 days to several weeks
  • BPC-157 has shown no reported toxicity in preclinical studies. The lethal dose (LD1) could not be established (Sikiric et al., 2013)
  • BPC-157 is not FDA-approved for any human use. The FDA has warned compounding pharmacies against producing it
  • Almost all published evidence comes from animal models. A 2026 review in the American Journal of Sports Medicine noted that BPC-157's benefits "are largely unvalidated in human trials" (Mayfield et al., 2026)

What the Research Literature Reports

Dosage Chart

Context Dose Frequency Duration Source
Rat Achilles tendon 10 mcg/kg i.p. Once daily 14 days Staresinic et al., 2003
Rat Achilles tendon 10 ng/kg i.p. Once daily 14 days Staresinic et al., 2003
Rat Achilles tendon 10 pg/kg i.p. Once daily 14 days Staresinic et al., 2003
Rat muscle crush injury 10 mcg/kg i.p. or topical Once daily 14 days Pevec et al., 2010
Mouse burn wound (topical) 50 mcg in cream Once daily Up to 21 days Mikus et al., 2001
Commonly reported human research dose 250-500 mcg subQ Once or twice daily 4-8 weeks Research literature consensus

Important note: The rat doses listed above were administered intraperitoneally (directly into the abdominal cavity), not subcutaneously. The commonly reported human research doses of 250-500 mcg are extrapolations, not verified clinical trial dosages. Talk to your physician before making any decisions.

Why Starting Low Matters

Researchers in animal models observed that BPC-157 was effective across a wide dose range. In the Achilles tendon study, all three dose levels (10 mcg/kg, 10 ng/kg, and 10 pg/kg) showed improvement over controls (Staresinic et al., 2003). The lowest dose was one million times smaller than the highest, yet still produced measurable effects.

This is unusual. Most compounds have a clear dose-response curve where more produces more effect. BPC-157 appears to work differently, at least in animal models.

For this reason, many researchers start with the lower end of the commonly reported range (250 mcg/day) before moving to higher doses. Without human dose-response data, there is no evidence that higher doses produce better outcomes.

Dose-Response: Animal Study Results

Dose (Rat) Effect on Achilles Tendon Tissue Source
10 mcg/kg/day Full tendon integrity restored by day 14, increased load to failure Tendon Staresinic et al., 2003
10 ng/kg/day Significant improvement in functional index and biomechanics Tendon Staresinic et al., 2003
10 pg/kg/day Measurable improvement over controls Tendon Staresinic et al., 2003
10 mcg/kg/day Reversed corticosteroid-impaired muscle healing Muscle Pevec et al., 2010

All doses are from animal models. No equivalent human dose-response data exists.

How Long to Take It

What the Studies Show

Animal studies on BPC-157 typically ran 14 to 21 days. The Achilles tendon study evaluated outcomes at days 1, 4, 7, 10, and 14. Full tendon integrity was restored by day 14 in treated rats (Staresinic et al., 2003). The burn wound study followed animals for 21 days (Mikus et al., 2001).

There are no long-term human studies. The commonly reported research protocol runs 4-8 weeks, but this is based on practitioner reports, not controlled trials.

What Happens When You Stop

This is an open question. In animal models, the healing effects (tendon integrity, collagen formation, functional recovery) persisted after the treatment period ended. The structural improvements were real tissue changes, not temporary effects that disappeared when the compound was removed.

Whether this holds true in humans, and for which conditions, is unknown. There is not enough data to say with confidence what happens after discontinuation.

Cycling Protocols

Protocol On Period Off Period Rationale
Standard 4 weeks 2 weeks Most commonly reported. Allows assessment of response.
Extended 8 weeks 4 weeks Reported for chronic conditions. Longer break to prevent receptor adaptation.
Injury-specific Until resolved (typically 4-6 weeks) N/A Some researchers report use only for the duration of an acute injury.

Cycling is commonly discussed in the research community, but there is no published data showing receptor desensitization with BPC-157. The off periods are precautionary. The idea is simple: give the body a break, reassess, and determine if continued use is warranted.

Talk to your physician about whether cycling is appropriate for your situation.

How to Prepare and Administer

Reconstitution Math

BPC-157 typically comes in 5 mg (5,000 mcg) vials as a lyophilized (freeze-dried) powder. It must be reconstituted with bacteriostatic water before use.

If your vial contains 5 mg (5,000 mcg) of BPC-157:

BAC Water Added Concentration Dose per 10 units (0.1 ml) Units for 250 mcg Units for 500 mcg
1 ml 5,000 mcg/ml 500 mcg 5 units (0.05 ml) 10 units (0.1 ml)
2 ml 2,500 mcg/ml 250 mcg 10 units (0.1 ml) 20 units (0.2 ml)

Most researchers use 2 ml of bacteriostatic water with a 5 mg vial. This makes the math simple: 10 units on an insulin syringe equals 250 mcg.

Step-by-step:

  1. Remove caps from both vials. Swab tops with alcohol.
  2. Draw 2 ml of bacteriostatic water into a sterile syringe.
  3. Insert the needle into the peptide vial at a 45-degree angle.
  4. Let the water run down the glass wall. Do not spray directly onto the powder.
  5. Gently swirl (never shake) until fully dissolved. The solution should be clear.
  6. Store reconstituted peptide in the refrigerator. Use within 28 days.

Common mistakes:

  • Spraying water directly onto the powder (can denature the peptide)
  • Shaking the vial (breaks peptide bonds)
  • Using regular sterile water instead of bacteriostatic water (no preservative means bacterial growth risk with multi-use vials)
  • Not refrigerating after reconstitution
  • Drawing from the vial without swabbing the rubber stopper

Injection Site and Technique

In research settings, BPC-157 is administered subcutaneously (under the skin) using an insulin syringe (29-31 gauge, 0.5 inch needle).

Two approaches are reported in the literature:

Local injection (near injury site): Some researchers administer BPC-157 subcutaneously as close to the affected tissue as possible. The theory is that local administration delivers a higher concentration to the target tissue. This is the more commonly reported approach for musculoskeletal injuries.

Systemic injection (abdomen): Others inject subcutaneously in the lower abdominal fat pad, similar to other peptide injection sites. This approach relies on systemic distribution.

The animal studies used intraperitoneal injection (into the abdominal cavity), which is not the same as subcutaneous. The translation from animal i.p. dosing to human subQ dosing is an extrapolation.

Injection site rotation: Rotate between the left and right sides of the lower abdomen, or alternate between the abdomen and the area near the target tissue. Avoid injecting into the same spot repeatedly.

Oral BPC-157: A Unique Property

BPC-157 has a property that sets it apart from most peptides: it is stable in human gastric juice (Sikiric et al., 2017). Most peptides are destroyed by stomach acid within minutes. BPC-157 survives the gastric environment because it is derived from a protein found naturally in gastric juice.

This means oral administration is a viable delivery route. In animal studies, researchers used both oral (in drinking water) and injectable routes, and both produced beneficial effects (Sikiric et al., 2013).

The tradeoff: Oral administration appears most effective for gastrointestinal conditions (gut healing, ulcers, inflammatory bowel issues). For musculoskeletal injuries (tendons, ligaments, muscles), injectable administration delivered closer to the injury site is more commonly reported in the literature.

Bioavailability differs between the two routes. Oral delivery exposes the GI tract to high local concentrations but may result in lower systemic levels reaching distant tissues. Injectable delivery bypasses the gut entirely.

Some researchers report using both routes simultaneously: oral for systemic and GI support, injectable for targeted musculoskeletal healing. There is no published data comparing the two routes head-to-head in humans.

Side Effects and Safety

The Human Data Gap

This section is short for an important reason: there is almost no human safety data for BPC-157.

A 2025 literature review noted that BPC-157 has "a desirable safety profile" based on preclinical studies, with "only a few side effects reported following its administration" (Jozwiak et al., 2025). In animal studies, researchers could not establish a lethal dose (LD1 not achieved), meaning toxicity was not observed even at very high doses (Sikiric et al., 2013).

A 2026 review in the American Journal of Sports Medicine was more cautious: "significant research regarding the safety and efficacy of these therapeutic methods is required before definitive recommendations can be made to patients" (Mayfield et al., 2026).

What Has Been Reported

The following side effects have been reported anecdotally (not in controlled trials):

Side Effect Frequency Notes
Injection site redness Occasional Typical of any subcutaneous injection
Mild nausea (oral) Rare Usually resolves within days
Lightheadedness Rare Reported at higher doses
Fatigue Rare Anecdotal reports only

What we do not know:

  • Long-term effects of repeated BPC-157 use in humans
  • Drug interactions with common medications
  • Effects during pregnancy or breastfeeding
  • Whether BPC-157 affects tumor growth (it promotes angiogenesis, which is a concern in cancer biology)
  • Dose-dependent side effect rates in humans

The angiogenesis concern deserves specific mention. BPC-157 promotes the growth of new blood vessels. This is beneficial for wound healing. It is potentially harmful if abnormal cell growth is already present. Anyone with a history of cancer should discuss this with their oncologist before considering BPC-157.

How BPC-157 Compares to Other Healing Peptides

Compound Common Research Dose Frequency Primary Research Focus Human Trial Data
BPC-157 250-500 mcg 1-2x daily Tendon, muscle, gut healing Minimal (IBD trials only)
TB-500 (Thymosin Beta-4) 2-5 mg 2x per week (loading), then weekly Tissue repair, angiogenesis, inflammation Limited
GHK-Cu 1-2 mg (injectable) or topical Daily Skin, wound healing, anti-inflammatory Limited (mostly topical studies)

BPC-157 vs. TB-500: Both are studied for tissue repair, but through different mechanisms. BPC-157 appears to work through growth factor upregulation and nitric oxide system modulation (Seiwerth et al., 2018). TB-500 (a synthetic fragment of Thymosin Beta-4) promotes cell migration and angiogenesis. They target overlapping but distinct pathways, which is why they are commonly discussed together.

BPC-157 vs. GHK-Cu: GHK-Cu (copper peptide) is primarily studied for skin regeneration and wound healing. It modulates gene expression related to collagen synthesis and has anti-inflammatory properties (Pickart et al., 2015). BPC-157 has a broader studied scope, covering tendon, muscle, bone, gut, and nerve tissue in animal models.

For the full profiles, see our TB-500 compound page and GHK-Cu compound page.

The Wolverine Stack: BPC-157 + TB-500

The combination of BPC-157 and TB-500 is the most commonly discussed peptide stack in the healing peptide space. It is nicknamed the "Wolverine stack" for obvious reasons.

Why People Combine Them

The rationale is straightforward. BPC-157 and TB-500 appear to promote tissue repair through different mechanisms. Stacking them aims to cover more biological pathways simultaneously.

  • BPC-157 upregulates growth factors (EGF, FGF, VEGF), modulates the nitric oxide system, and promotes collagen formation (Seiwerth et al., 2018)
  • TB-500 promotes cell migration to injury sites, reduces inflammation, and stimulates new blood vessel growth

Together, the theory is that they create a more complete healing environment than either compound alone.

Commonly Reported Stack Protocol

Compound Loading Phase (Weeks 1-2) Maintenance Phase (Weeks 3-8) Frequency
BPC-157 250-500 mcg 250 mcg 1-2x daily
TB-500 2-5 mg 2 mg 2x per week (loading), 1x per week (maintenance)

What the Evidence Actually Says

There are no published studies evaluating BPC-157 and TB-500 used together. Zero. The stack is based entirely on the individual research profiles of each compound and practitioner reports.

A 2026 review covering both peptides concluded that human orthopaedic data for TB-500 "are lacking" and noted that both TB-4 and TB-500 "remain banned substances in sports" (Mayfield et al., 2026).

The World Anti-Doping Agency (WADA) temporarily placed BPC-157 on its monitoring program in 2022. As of the latest review, it is not currently listed as banned by WADA, but athletes should verify the current status before use.

If you are considering this stack, discuss it with a qualified physician. There is no safety data on the combination.

How to Get BPC-157

Regulatory Status

BPC-157 is not FDA-approved for any human indication. In 2023, the FDA issued guidance advising compounding pharmacies against compounding BPC-157, citing insufficient safety data and a lack of an approved reference drug.

This means the legal landscape for obtaining BPC-157 is complicated. It sits in a gray area between research chemical and compounded pharmaceutical.

Compounding Pharmacies

Some 503A and 503B compounding pharmacies still compound BPC-157 under physician prescription in certain states. The legal status varies and is actively evolving. If you obtain BPC-157 through a compounding pharmacy, verify:

  • The pharmacy holds current state licensing
  • They operate under FDA-registered 503A or 503B status
  • They provide certificates of analysis (COA) with third-party purity testing
  • A licensed physician wrote the prescription

Research Chemical Suppliers

BPC-157 is widely available from research chemical vendors. These products are labeled "for research purposes only" and "not for human consumption." Quality varies enormously between vendors. Third-party testing and certificates of analysis are the minimum standard for evaluating purity.

Frequently Asked Questions {#faq}

How much BPC-157 should I take for tendon healing?

In the most cited animal study, researchers used 10 mcg/kg body weight once daily to heal transected Achilles tendons in rats. Full tendon integrity was restored by day 14 (Staresinic et al., 2003). The commonly reported human research dose is 250-500 mcg per day, but this is an extrapolation from animal data, not a verified human dose. Talk to your physician.

Is BPC-157 better taken orally or by injection?

It depends on the target tissue. BPC-157 is stable in gastric acid, which is rare for peptides (Sikiric et al., 2017). Oral administration is more commonly reported for gastrointestinal conditions. Injectable (subcutaneous) administration near the injury site is more commonly reported for musculoskeletal issues like tendon or muscle injuries. No human studies directly compare the two routes.

How long does BPC-157 take to work?

In animal studies, measurable improvements appeared within the first few days. Functional improvements in rat Achilles tendons were observed as early as day 4, with full recovery by day 14 (Staresinic et al., 2003). Anecdotal human reports typically describe noticing effects within 1-2 weeks, but these are not controlled observations.

Is BPC-157 safe?

Animal studies report no toxicity even at very high doses. The lethal dose could not be established in preclinical testing (Sikiric et al., 2013). However, there is almost no controlled human safety data. A 2026 sports medicine review stated that "significant research regarding the safety and efficacy" is still required (Mayfield et al., 2026). The absence of reported harm is not the same as proof of safety.

Can I stack BPC-157 with TB-500?

This is the most commonly discussed healing peptide stack. The compounds appear to work through different mechanisms, which is the theoretical basis for combining them. However, there are no published studies evaluating the combination. Safety and efficacy of the stack are unknown. Discuss this with a qualified physician.

Is BPC-157 FDA-approved?

No. BPC-157 is not FDA-approved for any human indication. The FDA has issued guidance advising compounding pharmacies against producing it. It has been used in early-phase clinical trials for inflammatory bowel disease in Croatia (Sikiric et al., 2006), but these trials have not led to FDA approval. It is classified as a research compound in the United States.

Medical Disclaimer

The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The editorial team shares published research findings, not medical recommendations. BPC-157 is not FDA-approved for any human indication. The FDA has advised compounding pharmacies against producing it. Nearly all published BPC-157 research comes from animal models. The absence of reported toxicity in animal studies is not equivalent to proven safety in humans. Talk to your physician.

Sources

  1. Staresinic M et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research, 21(6):976-83.
  2. Pevec D et al. (2010). Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Medical Science Monitor, 16(3):BR81-88.
  3. Sikiric P et al. (2013). Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design, 19(1):76-83.
  4. Sikiric P et al. (2017). Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Current Pharmaceutical Design, 23(27):4012-4028.
  5. Seiwerth S et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design, 24(18):1972-1989.
  6. Seiwerth S et al. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology, 12:627533.
  7. Jozwiak M et al. (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide. Pharmaceuticals, 18(2):185.
  8. Mayfield CK et al. (2026). Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 54(1):223-229.
  9. Mikus D et al. (2001). Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns, 27(8):817-27.
  10. Pickart L et al. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International.
  11. Sikiric P et al. (2006). Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease. Inflammopharmacology.

Schema Markup

{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Organization",
      "@id": "https://peptidenerds.com/#organization",
      "name": "Peptide Nerds",
      "url": "https://peptidenerds.com",
      "logo": {
        "@type": "ImageObject",
        "url": "https://peptidenerds.com/logo.png"
      },
      "sameAs": [
        "https://instagram.com/fatmaninthearena"
      ]
    },
    {
      "@type": "Article",
      "@id": "https://peptidenerds.com/blog/bpc-157-dosage#article",
      "headline": "BPC-157 Dosage Guide: How Much to Take, How Often, and For How Long (2026)",
      "datePublished": "2026-03-24T08:00:00-05:00",
      "dateModified": "2026-03-24T08:00:00-05:00",
      "author": {
        "@type": "Organization",
        "name": "Peptide Nerds Editorial Team",
        "url": "https://peptidenerds.com/about"
      },
      "publisher": {
        "@id": "https://peptidenerds.com/#organization"
      },
      "description": "Evidence-based BPC-157 dosage guide. Research literature doses, reconstitution math, cycling protocols, and the Wolverine stack explained. Updated March 2026.",
      "mainEntityOfPage": {
        "@type": "WebPage",
        "@id": "https://peptidenerds.com/blog/bpc-157-dosage"
      }
    },
    {
      "@type": "FAQPage",
      "@id": "https://peptidenerds.com/blog/bpc-157-dosage#faq",
      "mainEntity": [
        {
          "@type": "Question",
          "name": "How much BPC-157 should I take for tendon healing?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "In the most cited animal study, researchers used 10 mcg/kg body weight once daily to heal transected Achilles tendons in rats. Full tendon integrity was restored by day 14. The commonly reported human research dose is 250-500 mcg per day, but this is an extrapolation from animal data, not a verified human dose. Talk to your physician."
          }
        },
        {
          "@type": "Question",
          "name": "Is BPC-157 better taken orally or by injection?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "It depends on the target tissue. BPC-157 is stable in gastric acid, which is rare for peptides. Oral administration is more commonly reported for gastrointestinal conditions. Injectable subcutaneous administration near the injury site is more commonly reported for musculoskeletal issues like tendon or muscle injuries. No human studies directly compare the two routes."
          }
        },
        {
          "@type": "Question",
          "name": "How long does BPC-157 take to work?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "In animal studies, measurable improvements appeared within the first few days. Functional improvements in rat Achilles tendons were observed as early as day 4, with full recovery by day 14. Anecdotal human reports typically describe noticing effects within 1-2 weeks, but these are not controlled observations."
          }
        },
        {
          "@type": "Question",
          "name": "Is BPC-157 safe?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Animal studies report no toxicity even at very high doses. The lethal dose could not be established in preclinical testing. However, there is almost no controlled human safety data. A 2026 sports medicine review stated that significant research regarding safety and efficacy is still required. The absence of reported harm is not the same as proof of safety."
          }
        },
        {
          "@type": "Question",
          "name": "Can I stack BPC-157 with TB-500?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "This is the most commonly discussed healing peptide stack. The compounds appear to work through different mechanisms, which is the theoretical basis for combining them. However, there are no published studies evaluating the combination. Safety and efficacy of the stack are unknown. Discuss this with a qualified physician."
          }
        },
        {
          "@type": "Question",
          "name": "Is BPC-157 FDA-approved?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "No. BPC-157 is not FDA-approved for any human indication. The FDA has issued guidance advising compounding pharmacies against producing it. It has been used in early-phase clinical trials for inflammatory bowel disease in Croatia, but these trials have not led to FDA approval. It is classified as a research compound in the United States."
          }
        }
      ]
    }
  ]
}

Free Peptide Weight Loss Guide

Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.